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Preventable environmental causes of cancer, including tobacco smoke and other carcinogens in the diet, workplace, and ambient environment are
responsible for the vast majority of human cancers. This paper reviews recent molecular epidemiologic studies that have focused on environmental
carcinogenesis and environment-host interactions. Biomarkers such as carcinogen-DNA and carcinogen-protein adducts, mutations in reporter or
target genes (e.g., HPRT, GPA, ras, p53), or genetic or acquired susceptibility factors (e.g., polymorphisms in the P450 or glutathione-S-transferase
genes and serum levels of antioxidants) have shown significant potential in prevention. They should be useful in early identification of at risk
individuals and in designing and monitoring interventions (smoking cessation, exposure reduction, and chemoprevention). - Environ Health
Perspect 103(Suppl 8):233-236 (1995)
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Introduction
Environmental factors are implicated in
the vast majority ofhuman cancers. These
include exposures due to lifestyle (smoking,
diet, alcohol consumption), and carcino-
genic chemicals in the workplace and
general environment. In a complex interac-
tion, risk from these environmental expo-
sures is modulated by genetic and acquired
susceptibility factors. Genetic factors by
themselves are probably responsible for
only about 5 to 10% of cancers. Molecular
epidemiology has the potential to clarify
the contribution of environmental factors
to cancer causation and to identify high-
risk groups and individuals for purposes
ofprevention.
A considerable number of carcinogens
(agents known to be carcinogenic in exper-
imental systems and/or in humans) are
found routinely in the different environ-
mental media. Tobacco smoke contains
4-aminobiphenyl (4-ABP), polycyclic aro-
matic hydrocarbon (PAH), 4(N-methyl-
nitrosamino)-1-(3-pyridil)-1-butanone
(NNK), and many other carcinogens.
Diverse carcinogens are found in the food
supply, including aflatoxin, dichloro-
diphenyltrichloroethane (DDT), N-
nitrosodimethylamine (DMN), PAH, and
heterocyclic amines. Table 1 also lists
cancer-causing contaminants in the work-
place, drinking water, and the ambient air.
However, the contaminants listed in Table
1 represent only a small part of the prob-
lem because monitoring data are available
for a limited number ofchemicals. More-
over, an estimated 1000 new chemicals are
produced yearly and few ofthe more than
50,000 chemicals currently in commerce
have been sufficiently tested (1). From the
public health perspective, we need to know
what effects these agents are having at the
levels at which we are experiencing them,
and we need early warning systems to
detect those effects.
To prevent environmentally related
cancer, we must identify environmental
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risk factors in a more timely way and then
determine which groups and individuals
are at greatest risk. The next step is to
design interventions targeted to those
populations and individuals. Molecular
epidemiology has potential in this regard.
Molecular epidemiology fuses advances in
the molecular biology and molecular
genetics of cancer with epidemiology to
understand the molecular dose ofspecific
agents, their preclinical biological effects,
and the biologic factors that modulate
Table 1. Environmental carcinogens.
Carcinogens
Source identified Examples
Tobacco smoke >40 4-ABP, PAH, NNK, EtO,
benzene, arsenic
Food >40 AFB1, DDT/DDE,
DMN, PAH, PhIP,
EBDC
Workplace >50 Asbestos, benzene,
PAH, arsenic, ETS,
2, 4, 5-T
Drinking water >40 Benzene, chloroform,
alachlor, PAH, TCE,
DBCP
Air, indoor/outdoor >60 ETS, benzene,
formaldehyde, PAH,
radon, chlordane
Abbreviations: 4-ABP, 4-aminobiphenyl; PAH, poly-
cyclic aromatic hydrocarbon; NNK, 4 (N-methyl-
nitrosamino)-1-(3-pyridil)-l-butanone; EtO, ethylene
oxide; AFB1, aflatoxin B1; DDT, dichlorodiphenyl-
trichloroethane; DDE, dichlorodiphenyldichloro-
ethylene; DMN, N-nitrosodimethylamine; PhIP,
2-amino-i -methyl-6-phenylimidazo[4,5-blpyridine;
EBDC, ethylenebisdithiocarbamates; ETS, environ-
mental tobacco smoke; 2,4,5-T, 2,4,5-trichlorophen-
oxyacetic acid; TCE, trichloroethylene; DBCP,
1,2-dibromo-3-chloropropane.
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susceptibility to these exposures (2,3).
Biomarkers can thereby mitigate the two
problems that have plagued epidemio-
logy-the long latency of cancer and
fragmentary information on exposure.
Diverse biomarkers have been assayed
in human peripheral blood and other tis-
sues. They include internal dosimeters
such as cotinine (a metabolite ofnicotine)
an dichlorodiphenyldichloroethylene
(DDE) (a metabolite of DDT), molecular
dosimeters such as carcinogen-DNA and
carcinogen-protein adducts formed by
chemicals such as PAH and 4-ABP, and
preclinical effects such as chromosomal
aberrations, gene mutations, and changes
in the structure or function of oncogenes
and tumor-suppressor genes. The extent to
which biomarkers are modulated by
genetic and/or acquired susceptibility fac-
tors such as polymorphisms in the P450 or
glutathione transferase genes or serum levels
of antioxidant micronutrients have also
been studied. Several ofour recent studies
will be used here to illustrate the advantages
and limitations ofthis approach.
Tobacco smoke is a classic carcinogen
and has provided a valuable model for
validation of biomarkers, one with direct
relevance to cancer prevention. We have
recently studied biomarkers in 40 heavy
smokers enrolled in a smoking cessation
program. They were sampled at enrollment
while smoking, 10-weeks later, by which
time they had quit, and 6 and 12 months
after enrollment. The biomarkers measured
in peripheral blood included, cotinine,
PAH-DNA adducts in leukocytes, 4-
aminobiphenyl-hemoglobin (4-ABP-Hb)
adducts, and glycophorin-A (GPA) locus
mutation in erythrocytes. Cotinine, PAH-
DNA, and 4-ABP-Hb adducts were signi-
ficantly associated with smoking and
declined significantly after individuals quit
(Mooney et al., unpublished data). These
blood samples were also tested for genetic
and acquired factors believed to increase
susceptibility-the glutathione-S-trans-
ferase MI (GSTMI) null genotype and the
CYPlAllMspI genotype. Although some
epidemiologic studies have concluded that
these factors are not associated with
increased risk oflung cancer (4,5), others
have shown a significant association (6-9).
In subjects with the CYPlAllMspI poly-
morphism (heterozygotes and homozygotes
combined), PAH-DNA adduct levels were
only modestly higher than in those with
the wild-type CYPlAllMspI. However, a
significant association was seen between
PAH-DNA adducts and the exon 7
(Ile-Val) genotype. Among the smokers,
adduct levels were more than two times
higher in subjects with the Ile-Val
mutation (9.8 ± 8.6/108 nucleotides,
n= 10) than in subjects without the muta-
tion (4.5 ± 5.3/108 nucleotides, n= 148)
(p<0.01) (10). Although limited by small
numbers, this study indicates a possible
mechanism by which cancer risk from
smokingvaries within a population.
Passive smoking in the home affects as
many as 9 million American children
under the age of 5 years (11). Passive
smoking is associated with respiratory ill-
ness and lung cancer in nonsmokers
(12-14). Moreover, children may be at
heightened risk ofcancer later in life as a
result ofexposure to such carcinogens dur-
ing their early development (15,16).
Biomarkers can be useful in understanding
potential risks of environmental tobacco
smoke (ETS) to certain groups ofpeople
(including minorities, young children, and
women of reproductive age) by providing
direct measurements of the internal and
biologically effective dose ofETS, its mole-
cular effects, and susceptibility factors that
modulate it.
We have recently studied biomarkers
among Hispanic and African American
preschool children and their mothers with
varying exposures to ETS (17). Serum
cotinine and PAH-albumin adducts were
both significantly higher in the children
whose mothers smoked than in the chil-
dren of nonsmoking mothers (p< 0.001
and p<0.05, respectively). Cotinine levels
were also significantly higher in the chil-
dren whose mothers did not smoke but
who had ETS exposure from other house-
hold members than in the unexposed
children ofnonsmokers. There was a signi-
ficant dose-response relationship between
cotinine and the number of cigarettes
smoked per day by the mother both in
children (r2=0.23, p= 0.01) and in the
mothers (r2= 0.22, p=0.01). Among the
nonsmoking mothers, regression of bio-
markers against total passive smoking
exposure also showed a significant associa-
tion with cotinine (r2 =0.25, p= 0.04).
PAH-albumin did not show the same
dose-related response with the smoking
variables. Mothers' cotinine levels were
significantly correlated with those oftheir
children (r= 0.76, p < 0.00 1O), as were
PAH-albumin adducts (r=0.27,p=0.014).
These results highlight the need for smok-
ing cessation programs targeted to these
populations, particularly to younger
women ofreproductive age.
A second important environmental
exposure is ambient air pollution contain-
ing PAH and other products of fossil fuel
combustion. In Eastern Europe and other
highly industrialized areas, industry is a
major source ofthis type ofpollution, as is
residential coal burning. Through an inter-
national collaborative effort, we have stud-
ied biomarkers in residents ofthe Silesian
region in southwest Poland, which is heav-
ily industrialized, has high levels ofambi-
ent PAH, and also has high rates oflung
and other cancers (18). These subjects were
compared with residents from a rural area
in northeast Poland, which had roughly
10-fold lower levels of air pollution and
lower cancer rates. Biomarkers were mea-
sured in peripheral blood: PAH-DNA and
aromatic-DNA adducts, ras oncogene acti-
vation, sister chromatid exchange (SCE),
and chromosomal aberrations. All were ele-
vated in the environmentally exposed
group after adjusting for smoking and age.
Further, there were linear relationships
among ambient exposures and both mea-
sures of DNA adducts as well as SCE and
chromosomal aberrations.
So, what do these markers tell us about
potential risk? As a first step in answering
this question, we conducted a case-control
study of non-small cell carcinoma of the
lung, with more than 100 cases and a com-
parable number ofcontrols. A number of
biomarkers, induding PAH-DNA adducts,
were analyzed in peripheral blood from
cases and controls (19). After adjusting for
age, gender, season, ethnicity, and number
ofcigarettes smoked per day, PAH-DNA
adduct levels in white blood cells were
significantly associated with lung cancer.
The odds ratio (OR) was 2.75 (confidence
interval [CI] = 1.37-5.50) when PAH-
DNA adduct levels were stratified into
high and low categories. Such a finding
suggests that the ability to activate and
bind carcinogens efficiently may have been
a risk factor in the disease.
As mentioned, a polymorphism in the
GSTM1 gene has been associated in some
but not all (4,5) studies with risk oflung
cancer (8,9). Interestingly, in the case-con-
trol study described above, the odds of
lung cancer were 12-fold higher in people
with both high levels of adducts and the
GSTMI high-risk genotype (n= 10) than
in people without these factors (n= 84;
OR= 1.7, CI= 1.2-115, p= 0.04) (20).
Additional research is needed to confirm
these findings.
In a pilot study ofbiomarkers in breast
cancer, DNA adducts were detected in
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breast tissue from breast cancer cases and
controls by the 32P-postlabeling method
using the P1 nuclease extraction procedure
(21). This method detects aromatic
adducts, including those formed by
benzo[a]pyrene (BP) and other PAHs.
Results were available from 31 specimens,
including tumor and tumor-adjacent tissue
from 15 patients with breast cancer and 4
women undergoing reduction mammo-
plasty. Aromatic-DNA adduct levels were
lower among the noncancer patients than
in the cancer patients, although the num-
bers are too small to draw conclusions.
Smoking histories were available on the 15
cases. DNA samples from five ofthe seven
smokers (tumor or tumor-adjacent tissue)
displayed the characteristic pattern of
smoking-related adducts (a diagonal zone of
radioactivity) that has been reported in pre-
vious studies oflung cancer patients (22).
None ofthe samples from the nonsmokers
or from the mammoplasty controls showed
this characteristic smoking-related pattern.
These findings are interesting in light of
the mixed results from epidemiologic stud-
ies ofsmoking and breast cancer risk. Most
studies ofactive smoking have found either
a small positive association or no associa-
tion with breast cancer (23). Some investi-
gators have hypothesized that smoking has
the potential to affect breast cancer risk by
two competing mechanisms: a) reducing
risk by altering estrogen metabolism; and
b) increasing risk by directly exposing
breast tissue to genotoxic carcinogens such
as PAHs (24-27). The data from this pilot
study demonstrate that carcinogens found
in cigarette smoke, diet, and other environ-
mental media reach the breast and damage
DNA. Measurement ofcarcinogen-DNA
adducts as biomarkers ofgenetic damage
may permit identification ofwomen poten-
tially at highest risk from smoking and
other carcinogen exposures. Additional
samples are nowbeinganalyzed.
Biomarkers have the potential to help
us understand interindividual variability in
cancer risk and differential risks to subsets
of the population. An investigation of
mothers and newborns in Eastern Europe
has shown higher levels of both cotinine
and PAH-DNA adducts in the cord blood
ofnewborns than in their mothers, which
is quite surprising given that in utero expo-
sure to both compounds is likely to be
10-fold lower for the fetus than for the
mother. This finding suggests developmen-
tally related susceptibility to tobacco smoke
and environmental PAH. The fetus
appears to be less protected against DNA
damage than the mother, which isconsis-
tentwith experimental data.
This study is evaluating gene-environ-
ment interactions by measuring the molecu-
lar effect of the CYPIAI and GSTMI
genotypes in the newborns. Those infants
with the CYPJAllMspI variant genotype
(n=28) had higher levels of DNA damage
[PAH-DNA adducts by enzyme-linked
immunosorbent assay (ELISA)] than those
without (n= 106). This difference was of
borderline significance after controlling for
plasma cotinine, place ofresidence, coal use,
diet, and occupational exposures (p=0.07).
Conclusion
Biomarkers have potential in intervention.
As shown in the smokenders study, they
can document a decline after exposure
reduction (28). They can also demonstrate
modulation of DNA damage by serum
antioxidant vitamins. The antioxidants,
vitamins C, E, n-carotene, and retinoids,
have been shown experimentally to reduce
carcinogen activation, adduct formation,
mutation, and tumor formation; as some
studies indicate a protective effect against
human epithelial cancers (29-31). An
inverse association has also been found
between serum levels of several of these
micronutrients and carcinogen-DNA
adducts (32). These results support the use-
fulness ofbiomarkers as intermediate end
points in monitoring the effects ofchemo-
prevention. In fact, biomarkers are already
being incorporated into chemoprevention
trials as intermediate end points (33).
Although more research is needed to
fully validate this approach, the results to
date are encouraging and suggest that
molecular epidemiology ultimately may
prove to be a useful tool in prevention of
environmentally related cancer.
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